![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genentech’s Rituxin Secures FDA Pediatric Indications for B-Cell Cancers
Genentech’s Rituxin Secures FDA Pediatric Indications for B-Cell Cancers
Genentech’s Rituxin (rituximab) has received several FDA approvals for use along with chemotherapy for treatment of four B-cell cancers in pediatric patients.
The cancers consist of CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia.
The approvals were supported by positive survival data from an open-label global study evaluating Rituxin in patients with CD20-positive previously untreated, advanced stage forms of the cancers.
Upcoming Events
-
18Jul
-
21Oct